Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
Abstract Number: 42 • 2019 ACR/ARP Annual Meeting
Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
Sheila Arvikar¹, Hatice Hasturk ², Klemen Strle ¹, Marcy Bolster ¹, Deborah Collier ¹, Alpdogan Kantarci ² and Allen Steere ¹, ¹Massachusetts General Hospital, Boston, MA, ²Forsyth, Cambridge, MA
Background/Purpose: Periodontitis and immune responses to periodontal pathogens such as Porphyromonas gingivalis (Pg) are associated with rheumatoid arthritis (RA) but the mechanisms underlying these connections…
Abstract Number: 177 • 2019 ACR/ARP Annual Meeting
Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal
Mariana Luís¹, Salomé Garcia ², Francisca Guimarães ³, Manuel António ⁴, Ana Fernandes ⁵, Filipe Araújo ⁶, Rita Cunha ⁷, Maura Couto ⁸, Ana Pinto ⁹, Lígia Silva ¹⁰, Margarida Cruz ¹¹, Jose Pereira da Silva ¹² and Catia Duarte ¹³, ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Centro Hospitalar São João, Porto, Portugal, ³Centro Hospitalar do Alto Minho, Ponte de Lima, Portugal, ⁴Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Centro Hospitalar do Algarve, Faro, Portugal, ⁶Hospital Ortopédico de Sant’Ana, Lisboa, Portugal, ⁷Centro Hospitalar Baixo Vouga, Aveiro, Portugal, ⁸Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁹Unidade Local de Saúde da Guarda, Guarda, Portugal, ¹⁰Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹¹Centro Hospitalar do Oeste, Caldas da Rainha, Portugal, ¹²Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, ¹³Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal
Background/Purpose: Work disability is a common consequence of Rheumatoid Arthritis (RA) with economic implications for both the patient and society. Scarce information is available on…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
Abstract Number: 462 • 2019 ACR/ARP Annual Meeting
The Endogenous Plasma Small RNAome of Rheumatoid Arthritis
Michelle Ormseth¹, Joseph Solus ², Quanhu Sheng ², Fei Ye ², Haocan Song ², Qiong Wu ², Yan Guo ³, Annette Oeser ², Ryan Allen ², Kasey Vickers ² and C. Michael Stein ², ¹Vanderbilt University Medical Center and Veterans Administration: TN Valley Healthcare System, Nashville, ²Vanderbilt University Medical Center, Nashville, ³University of New Mexico, Albuquerque
Background/Purpose: Small RNA (sRNA) sequencing has revealed new classes of sRNAs beyond microRNAs. These sRNAs can regulate genes and are also useful biomarkers of disease.…
Abstract Number: 498 • 2019 ACR/ARP Annual Meeting
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Barbara Mascialino¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…
Abstract Number: 545 • 2019 ACR/ARP Annual Meeting
Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study
Samantha Lent ¹, Thierry Sornasse ², Robert Georgantas ¹, Jeremy Sokolove ² and Iain McInnes³, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie Immunology Clinical Development, Redwood City, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response to conventional…
Abstract Number: 847 • 2019 ACR/ARP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Mark Genovese¹, Josef Smolen ², Tsutomu Takeuchi ³, Gerd Burmester ⁴, Dennis Brinker ⁵, Terence Rooney ⁵, Jinglin Zhong ⁶, Daojun Mo ⁵, Chadi Saifan ⁵, Anabela Cardoso ⁵, Maher Issa ⁵, Wen-Shuo Wu ⁵ and Kevin Winthrop ⁷, ¹Stanford University, Stanford, CA, ²Medical University of Vienna, Vienna, Austria, ³Keio University School of Medicine, Tokyo, Japan, ⁴Charité—University Medicine Berlin, Berlin, Germany, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶IQVIA, Morrisville, NC, ⁷Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
Abstract Number: 980 • 2019 ACR/ARP Annual Meeting
Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
Ana Igea ¹, Tiago Carvalheiro ², Beatriz Malvar Fernandez ², Angela Rodriguez-Trillo ³, Trudy McGarry ⁴, Carmen Conde ⁵, Douglas Veale ⁶, Ursula Fearon ⁷, Africa Gonzalez ¹, Timothy R.D. Radstake ⁸, Kris A. Reedquist ² and Samuel Garcia⁹, ¹Department of Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain, ²Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, ³laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS)-Hospital Clinico (CHUS), Santiago de Compostela, Spain, ⁴Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland, ⁵Laboratorio de Reumatología Experimental y Observacional, y Servicio de Reumatología, Instituto de Investigacion Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain, ⁶EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁸Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Spain
Background/Purpose: The semaphorin family is a large group of proteins initially described in axon guidance. However, semaphorins also play a role in other processes involved…
Abstract Number: 1184 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments
Caroline Paris ¹, Pierre Lafforgue ¹, Vincent Pradel ², Christophe Richez ³ and Thao Pham¹, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²APHM -Assistance publique des hôpitaux de Marseille, Marseille, Finland, ³Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: The assessment of active joints is a core component of widely used outcome measures in rheumatoid arthritis (RA). However, variability exists within and across…
Abstract Number: 1347 • 2019 ACR/ARP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies
Vibeke Norvang¹, Gina Hetland Brinkmann ², Kazuki Yoshida ³, Siri Lillegraven ⁴, Anna-Birgitte Aga ⁵, Joe Sexton ⁴, Sara K. Tedeschi ⁶, Till Uhlig ¹, Tore Kvien ¹, Maria Dahl Mjaavatten ⁴, Daniel Solomon ⁷, Espen Haavardsholm ¹ and Houchen Lyu ⁸, ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Østfold Hospital Trust, Dept. of Rheumatology, Grålum, Norway, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁵Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: A treat-to-target (TTT) approach results in superior outcomes compared to conventional care in patients with rheumatoid arthritis (RA). However, TTT strategies are still not…
Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Vibeke Strand¹, Janet Pope ², John Woolcott ³, Jose L. Rivas ⁴, Annette Diehl ³, Shixue Liu ⁵, David Gruben ⁶ and Stanley Cohen ⁷, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Western University, London, ON, Canada, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Shanghai, China (People's Republic), ⁶Pfizer Inc, Groton, CT, ⁷Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…
Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Alberto Migliore¹, Giuseppe Pompilio ², Davide Integlia ², Joe Zhuo ³ and Evo Alemao ⁴, ¹Unit of Rheumatology Ospedale S. Pietro Fatebenefratelli, Rome, Italy, ²Isheo Srl, Rome, Italy, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Princeton

Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…
Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].